{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:52:05Z","timestamp":1788861125787,"version":"build-2803163510"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.2169\/internalmedicine.4569-24","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T18:11:06Z","timestamp":1727979066000},"page":"41-45","source":"Crossref","is-referenced-by-count":7,"title":["The Basis of Anti-A\u03b2 Antibody Therapy: The Toxicity of A\u03b2 Aggregates and the Mechanism of Action of Anti-A\u03b2 Antibodies"],"prefix":"10.2169","volume":"65","author":[{"given":"Kenjiro","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Noguchi-Shinohara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Watanabe-Nakayama","sequence":"additional","affiliation":[{"name":"WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ono K, Watanabe-Nakayama T. Aggregation and structure of amyloid \u03b2-protein. Neurochem Int 151: 105208, 2021.","DOI":"10.1016\/j.neuint.2021.105208"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ono K. Alzheimer&apos;s disease as oligomeropathy. Neurochem Int 119: 57-70, 2018.","DOI":"10.1016\/j.neuint.2017.08.010"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&apos;s disease. Nature 349: 704-706, 1991.","DOI":"10.1038\/349704a0"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Citron M, Oltersdorf T, Haass C, et al. Mutation of the \u03b2-amyloid precursor protein in familial Alzheimer&apos;s disease increases \u03b2-protein production. Nature 360: 672-674, 1992.","DOI":"10.1038\/360672a0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The &apos;Arctic&apos; APP mutation (E693G) causes Alzheimer&apos;s disease by enhanced A\u03b2 protofibril formation. Nat Neurosci 4: 887-893, 2001.","DOI":"10.1038\/nn0901-887"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer&apos;s disease and age-related cognitive decline. Nature 488: 96-99, 2012.","DOI":"10.1038\/nature11283"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid \u03b2-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272: 22364-22372, 1997.","DOI":"10.1074\/jbc.272.35.22364"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Watanabe-Nakayama T, Ono K, Itami M, Takahashi R, Teplow DB, Yamada M. High-speed atomic force microscopy reveals structural dynamics of amyloid \u03b21-42 aggregates. Proc Natl Acad Sci U S A 113: 5835-5840, 2016.","DOI":"10.1073\/pnas.1524807113"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ono K, Tsuji M. Protofibrils of amyloid-\u03b2 are important targets of a disease-modifying approach for Alzheimer&apos;s disease. Int J Mol Sci 21: 952, 2020.","DOI":"10.3390\/ijms21030952"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tycko R. Amyloid polymorphism: structural basis and neurobiological relevance. Neuron 86: 632-645, 2015.","DOI":"10.1016\/j.neuron.2015.03.017"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hasecke F, Miti T, Perez C, et al. Origin of metastable oligomers and their effects on amyloid fibril self-assembly. Chem Sci 9: 5937-5948, 2018.","DOI":"10.1039\/C8SC01479E"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Watanabe-Nakayama T, Tsuji M, Umeda K, et al. Structural dynamics of amyloid-\u03b2 protofibrils and actions of anti-amyloid-\u03b2 antibodies as observed by high-speed atomic force microscopy. Nano Lett 23: 6259-6268, 2023.","DOI":"10.1021\/acs.nanolett.3c00187"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Johannesson M, S\u00f6derberg L, Zachrisson O, et al. Lecanemab demonstrates highly selective binding to A\u03b2 protofibrils isolated from Alzheimer&apos;s disease brains. Mol Cell Neurosci 130: 103949, 2024.","DOI":"10.1016\/j.mcn.2024.103949"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Butterfield SM, Lashuel HA. Amyloidogenic protein-membrane interactions: mechanistic insight from model systems. Angew Chem Int Ed Engl 49: 5628-5654, 2010.","DOI":"10.1002\/anie.200906670"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yasumoto T, Takamura Y, Tsuji M, et al. High molecular weight amyloid \u03b2<sub>1-42<\/sub> oligomers induce neurotoxicity <i>via<\/i> plasma membrane damage. FASEB J 33: 9220-9234, 2019.","DOI":"10.1096\/fj.201900604R"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Abbasi J. Promising results in 18-month analysis of Alzheimer drug candidate. JAMA 320: 965, 2018.","DOI":"10.1001\/jama.2018.13027"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer&apos;s disease. N Engl J Med 388: 9-21, 2023.","DOI":"10.1056\/NEJMoa2212948"},{"key":"18","unstructured":"18. AlzForum Foundation Inc., Alzforum [Internet]. [cited 2024 Aug 15]. Available from: https:\/\/www.alzforum.org\/therapeutics\/leqembi"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 59: 1313-1319, 2002.","DOI":"10.1212\/01.WNL.0000031421.50369.E7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Noguchi-Shinohara M, Yuki S, Dohmoto C, et al. Consumption of green tea, but not black tea or coffee, is associated with reduced risk of cognitive decline. PLoS One 9: e96013, 2014.","DOI":"10.1371\/journal.pone.0096013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ono K, Condron MM, Ho L, et al. Effects of grape seed-derived polyphenols on amyloid \u03b2-protein self-assembly and cytotoxicity. J Biol Chem 283: 32176-32187, 2008.","DOI":"10.1074\/jbc.M806154200"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kimura AM, Tsuji M, Yasumoto T, et al. Myricetin prevents high molecular weight A\u03b2<sub>1-42<\/sub> oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria. Free Radic Biol Med 171: 232-244, 2021.","DOI":"10.1016\/j.freeradbiomed.2021.05.019"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330: 512-527, 2023.","DOI":"10.1001\/jama.2023.13239"},{"key":"24","unstructured":"24. AlzForum Foundation Inc., Alzforum [Internet]. [cited 2024 Aug 15]. Available from: https:\/\/www.alzforum.org\/therapeutics\/donanemab"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_4569-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T03:26:15Z","timestamp":1767410775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_4569-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4569-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"4569-24"}}